Amarin Corp PLC (AMRN)
0.8689
+0.01
(+1.02%)
USD |
NASDAQ |
Apr 26, 15:41
Amarin SG&A Expense (Quarterly): 43.94M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 43.94M |
September 30, 2023 | 45.46M |
June 30, 2023 | 50.95M |
March 31, 2023 | 59.59M |
December 31, 2022 | 68.13M |
September 30, 2022 | 58.74M |
June 30, 2022 | 86.89M |
March 31, 2022 | 90.65M |
December 31, 2021 | 92.37M |
September 30, 2021 | 102.96M |
June 30, 2021 | 107.20M |
March 31, 2021 | 105.80M |
December 31, 2020 | 116.82M |
September 30, 2020 | 120.16M |
June 30, 2020 | 92.40M |
March 31, 2020 | 133.94M |
December 31, 2019 | 96.02M |
September 30, 2019 | 82.56M |
June 30, 2019 | 73.41M |
March 31, 2019 | 71.63M |
December 31, 2018 | 79.69M |
September 30, 2018 | 49.96M |
June 30, 2018 | 53.94M |
March 31, 2018 | 43.41M |
December 31, 2017 | 35.64M |
Date | Value |
---|---|
September 30, 2017 | 33.19M |
June 30, 2017 | 31.54M |
March 31, 2017 | 34.17M |
December 31, 2016 | 31.22M |
September 30, 2016 | 26.06M |
June 30, 2016 | 26.07M |
March 31, 2016 | 28.02M |
December 31, 2015 | 23.52M |
September 30, 2015 | 26.73M |
June 30, 2015 | 26.05M |
March 31, 2015 | 24.75M |
December 31, 2014 | 18.40M |
September 30, 2014 | 19.60M |
June 30, 2014 | 21.20M |
March 31, 2014 | 20.66M |
December 31, 2013 | 22.27M |
September 30, 2013 | 28.00M |
June 30, 2013 | 34.96M |
March 31, 2013 | 39.72M |
December 31, 2012 | 19.52M |
September 30, 2012 | 14.59M |
June 30, 2012 | 11.78M |
March 31, 2012 | 11.65M |
December 31, 2011 | 6.47M |
September 30, 2011 | 3.433M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
43.94M
Minimum
Dec 2023
133.94M
Maximum
Mar 2020
85.68M
Average
90.65M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
Trinity Biotech PLC | 7.681M |
DBV Technologies SA | 6.443M |
Adaptimmune Therapeutics PLC | 16.88M |
Akari Therapeutics PLC | -- |
Biodexa Pharmaceuticals Plc | -- |